Hepatology Communications

Article	Citations
Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population	165
Single‐Cell, Single‐Nucleus, and Spatial RNA Sequencing of the Human Liver Identifies Cholangiocyte and Mesenchymal Heterogeneity	127
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH	117
Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH	107
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD	84
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis	76
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease	73
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States	69
Hepatic Stellate Cell Regulation of Liver Regeneration and Repair	61
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection	60
Iron overload disorders	57
Human Nonalcoholic Steatohepatitis on a Chip	54
A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma	54
Genome‐Wide Association Study of NAFLD Using Electronic Health Records	50
Exosome-Like Nanoparticles From Lactobacillus rhamnosus GG Protect Against Alcohol-Associated Liver Disease Through Intestinal Aryl Hydrocarbon Receptor in Mice	50
Covid‐19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis	50
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH	48
Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials	47
Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update	46
Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016	46
Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting	46
Liver Fibrosis Index FIB‐4 Is Associated With Mortality in COVID‐19	45
Artificial intelligence-based text generators in hepatology: ChatGPT is just the beginning	43
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning	43
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis	43

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD	42
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis	42
Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis	41
Alcohol‐Associated Liver Disease Before and After COVID‐19—An Overview and Call for Ongoing Investigation	41
Impact of COVID‐19 in Liver Disease Progression	40
Effect of Omega‐3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD	39
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study	38
Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study	37
Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma	37
Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6	37
Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis	37
Hepcidin Signaling in Health and Disease: Ironing Out the Details	36
Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients	35
Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies	34
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019	34
SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination	33
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma	33
The Impact of COVID-19 on Organ Donation, Procurement, and Liver Transplantation in the United States	33
Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol	33
The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017	32
Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity	32
Intratumoral Microbiome of Human Primary Liver Cancer	32
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis	32
Assessment of the Frail Patient With End‐Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and Disability	31
Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis	31
Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection	31
Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study	31
Impacts of Early Kasai Portoenterostomy on Short-Term and Long-Term Outcomes of Biliary Atresia	31
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance	31
Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes	30
Single‐cell transcriptomics reveals conserved cell identities and fibrogenic phenotypes in zebrafish and human liver	29
COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter	29
Transcriptomic Cross‐Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice	29
Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data	29
Hepatocyte TGF‐β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let‐7b‐5p	28
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease	28
Intestinal virome in patients with alcohol use disorder and after abstinence	28
Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient	28
American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease	27
Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation	27
Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis	27
Tinospora Cordifolia (Giloy)–Induced Liver Injury During the COVID‐19 Pandemic—Multicenter Nationwide Study From India	27
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study	27
Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy	27
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis	27
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany	27
Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity	27
CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma	27
The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis	27
Associations Between Alcohol Use and Liver‐Related Outcomes in a Large National Cohort of Patients With Cirrhosis	27

Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	27
Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort	26
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis	26
A Dynamic Aspartate‐to‐Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease	25
Primary biliary cholangitis: Epidemiology, prognosis, and treatment	25
Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests	25
Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus	25
Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies	24
Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B	24
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study	24
Innovations in Hepatitis C Screening and Treatment	24
Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity	23
Hepatic NF‐κB‐Inducing Kinase and Inhibitor of NF‐κB Kinase Subunit α Promote Liver Oxidative Stress, Ferroptosis, and Liver Injury	23
Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir	23
High‐Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer’s Disease	23
Growth hormone deficiency and NAFLD: An overlooked and underrecognized link	23
The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease Study 2019	23
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B	23
Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver‐Related Events in Nonalcoholic Fatty Liver Disease	22
Urgent Liver Transplantation Soon After Recovery From COVID-19 in a Patient With Decompensated Liver Cirrhosis	22
Integrin subunit beta 8 contributes to lenvatinib resistance in HCC	22
Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments	22
Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review	22
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC	22
Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα‐FGF21 Axis	22
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	22
Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth	21
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma	20
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial	20
Setting up criteria for drug‐induced autoimmune‐like hepatitis through a systematic analysis of published reports	20
Correlation Between Clinical and Pathological Findings of Liver Injury in 27 Patients With Lethal COVID‐19 Infections in Brazil	20
The Exosome‐Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus	20
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?	20
Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020	20
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways thro	19
Clinical phenotype of adult‐onset liver disease in patients with variants in ABCB4 , ABCB11 , and ATP8B1	19
COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality	19
Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD	19
Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China	19
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis	19
Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome	18
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1	18
Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis	18
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus	18
Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990‐2019	17
Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids	17
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga	17
Clinical Staging of Mass‐Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging	17
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB	17
Liver Injury as a Surrogate for Inflammation and Predictor of Outcomes in COVID-19	17
Associations between six dietary habits and risk of hepatocellular carcinoma: A Mendelian randomization study	17
Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis	17
Left atrial dysfunction is an independent predictor of mortality in patients with cirrhosis treated by transjugular intrahepatic portosystemic shunt	17
Heterozygosity of the Alpha 1‐Antitrypsin Pi*Z Allele and Risk of Liver Disease	17
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model	17
Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury	17
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta	17
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma	16
The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States	16
Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey‐Based Study	16
National Early Career Transplant Hepatologist Survey: Compensation, Burnout, and Job Satisfaction	16
High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module	16
Sarcopenia, healthy living, and mortality in patients with chronic liver diseases	16
Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing	16
Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial	15
Ashwagandha-induced liver injury—A case series from India and literature review	15
Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature	15
Fatty Liver and the Coronavirus Disease 2019 Pandemic: Health Behaviors, Social Factors, and Telemedicine Satisfaction in Vulnerable Populations	15
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	15
Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice	15
Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC	15
Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH	15
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B	15
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action	15
Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease	15
Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics	15
Loss of Coordinated Neutrophil Responses to the Human Fungal Pathogen, Candida albicans, in Patients With Cirrhosis	15
Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex	15
Assessing the risk of surgery in patients with cirrhosis	15
High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases	14

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species	14
Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community‐Based Sample of Mexican‐Origin Adults	14
Risk Associations of Glycemic Burden and Obesity With Liver Cancer—A 10‐Year Analysis of 15,280 Patients With Type 2 Diabetes	14
An RNA Interference/Adeno‐Associated Virus Vector–Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus	14
The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis	14
Hepatic Predictors of Mortality in Severe Acute Respiratory Syndrome Coronavirus 2: Role of Initial Aspartate Aminotransferase/Alanine Aminotransferase and Preexisting Cirrhosis	14
Developing Priorities for Palliative Care Research in Advanced Liver Disease: A Multidisciplinary Approach	14
Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals	14
An Experimental DUAL Model of Advanced Liver Damage	14
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature	14
Cognitive Impairment and Physical Frailty in Patients With Cirrhosis	14
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018	14
Transcriptional Analysis of Liver Tissue Identifies Distinct Phenotypes of Indeterminate Pediatric Acute Liver Failure	14
Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care	14
Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C	13
The COVID‐19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase‐1, and Excessive Hydrolysis Increases Cytotoxicity	13
Myeloid Endoplasmic Reticulum Resident Chaperone GP96 Facilitates Inflammation and Steatosis in Alcohol‐Associated Liver Disease	13
Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation	13
Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD	13
Automated Measurements of Body Composition in Abdominal CT Scans Using Artificial Intelligence Can Predict Mortality in Patients With Cirrhosis	13
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway	13
Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis	13
Interferon Type I Regulates Inflammasome Activation and High Mobility Group Box 1 Translocation in Hepatocytes During Ehrlichia -Induced Acute Liver Injury	13
Management of alcohol use disorder in patients with chronic liver disease	13
Gasdermin D–mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy	13
Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy	13
Male‐Specific Activation of Lysine Demethylases 5B and 5C Mediates Alcohol‐Induced Liver Injury and Hepatocyte Dedifferentiation	13
Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study	13
Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses	13
A Population‐Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection	13
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disea	13
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis	13
Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response	13
High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study	13
STE20‐Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes	13
Evaluation of IL‐6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis	13
Frailty and the Risk of Acute Kidney Injury Among Patients With Cirrhosis	13
Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis	13
RORα Enhances Lysosomal Acidification and Autophagic Flux in the Hepatocytes	13
A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma	12
The Matrisome Genes From Hepatitis B–Related Hepatocellular Carcinoma Unveiled	12
Redundant Functions of ERK1 and ERK2 Maintain Mouse Liver Homeostasis Through Down‐Regulation of Bile Acid Synthesis	12
Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory‐Wide Cohort Study	12
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population	12
Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol-Associated Liver Disease	12
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement	12
Hepatic Adenosine Triphosphate Reduction Through the Short‐Chain Fatty Acids–Peroxisome Proliferator‐Activated Receptor γ–Uncoupling Protein 2 Axis Alleviates Immune‐Mediated Acute Hepatitis in Inulin	12
The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children	12
Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis	12
How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study	12
FXR and NASH: an avenue for tissue-specific regulation	12
TGFβ‐induced FOXS1 controls epithelial–mesenchymal transition and predicts a poor prognosis in liver cancer	12
Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy	12
Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact	12
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	12
Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status	12
Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acute‐On‐Chronic Liver Failure	12
Alcohol‐associated fibrosis in females is mediated by female‐specific activation of lysine demethylases KDM5B and KDM5C	12
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis	12
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure	12
Health‐Related Quality of Life and Its Contributors According to a Preference‐Based Generic Instrument in Cirrhosis	12
Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo‐Independent Regulation of Heat Shock Protein 70 Family Members	12
Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice	12
Early Allograft Dysfunction Increases Hospital Associated Costs After Liver Transplantation—A Propensity Score–Matched Analysis	12
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores	12
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States	12
The unfolded protein response to PI*Z alpha‐1 antitrypsin in human hepatocellular and murine models	12
Detection of Hepatitis B Virus–Host Junction Sequences in Urine of Infected Patients	12
Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure	11
Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers	11
Letter to the editor: The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 protein	11
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy	11
Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial	11
Metabolomic Analysis Uncovers Energy Supply Disturbance as an Underlying Mechanism of the Development of Alcohol‐Associated Liver Cirrhosis	11
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	11
Patterns of kidney dysfunction in acute‐on‐chronic liver failure: Relationship with kidney and patients’ outcome	11
Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH	11
Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models	11
WNT7B Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis	11
Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma	11
Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis	11
Patterns of Inpatient Opioid Use and Related Adverse Events Among Patients With Cirrhosis: A Propensity‐Matched Analysis	11
Targets and study design for symptom-focused trials aimed at patients with cirrhosis: An expert consensus	11
Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis	11
Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma	11
Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study	11
Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure	11
Tissue‐Specific Regulation of Ferroportin in Wild‐Type and Hjv‐/‐ Mice Following Dietary Iron Manipulations	11
Shelter‐Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness	11
Interaction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus di	11
Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis	11
Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice	11
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	11
The emotional burden of caregiving for patients with cirrhosis	11
Artificial intelligence compared with human-derived patient educational materials on cirrhosis	11